A new clinical trial for Eledon Pharmaceutical's tegoprubart is underway — and the first participant with type 1 diabetes (T1D) and reduced kidney function has received their islet transplant! Breakthrough T1D is funding a clinical trial at the University of Chicago and the University of Miami that replaces tacrolimus, a traditional immunosuppressant, with tegoprubart, a milder and more targeted alternative, in islet transplants for people with T1D and reduced kidney function. Tacrolimus can damage the kidneys and the transplanted islet cells, so people with reduced kidney function have previously been excluded from these transplants. Nearly a third of people with T1D will develop kidney disease. This study could open islet transplants to a larger population of people with T1D. Learn more here: breakthrought1d.org/news-and…

Day 2 of our Clinical Research Congress brought incredible conversations surrounding global collaboration, unmet needs for those in the type 1 diabetes (T1D) community, disease modifying therapies, and more. We are extremely thankful to have so many brilliant minds together in one place helping move us toward cures and improving lives for everyone living with T1D. Click here for the full recap: breakthrought1d.org/news-and…

Jim Lurie, whose parents, Carol and Erwin, were two founders of our organization over 50 years ago, kicks off the third and final day of the inaugural Breakthrough T1D Clinical and Research Congress. Stay tuned for more news and updates as we wrap up an incredible weekend, back where it all began here in Philadelphia.

Hearing the lived experiences of patients with type 1 diabetes (T1D) like Ramya and Ben gives Breakthrough T1D funded researchers a unique perspective on the real-world impact of their work. Be sure to stay tuned this weekend across our social channels as we bring you the latest and greatest T1D research news coming out of the inaugural Breakthrough T1D Clinical and Research Congress!

ICYMI: Katie Beth Hand was featured on NBC Nightly News! Katie Beth is a participant in a Breakthrough T1D-funded clinical trial at the University of Chicago that is pairing deceased donor islet transplants with tegoprubart, an investigational therapy by @Eledon_Pharma to protect transplanted cells without the harsh side effects of traditional immunosuppressants. 13 years after her diagnosis, Katie Beth is off external insulin. We're proud to support this research and grateful to Katie Beth for sharing her story and participating in this study. Watch the feature here: youtube.com/watch?v=Tx1GXI62…

If you or someone you know lives with type 1 diabetes (T1D) and is in the path of #HurricaneNolo make sure you're prepared! Visit the link below for helpful resources and stay safe! bit.ly/3BeTUaf

The T1D community has been clear: deceased donor islets (DDIs) must be accessible for those who qualify. Earlier this year, Breakthrough T1D went to work, submitting a proposal to the Department of Health and Human Services (HHS) and meeting with FDA and the Health Resources and Services Administration to urge a change. Today we’re seeing real, tangible movement. HHS published a Request for Information on potential changes to the regulation of deceased donor islets—the first step toward a policy change. In other words, they want to hear from you. Read the RFI and submit your comments here. Look for the comment button on the top left of the page: regulations.gov/document/FDA…

The Food and Drug Administration is a critical partner in accelerating cures and therapies for type 1 diabetes. The nominee to run FDA knows first-hand how important that is. Dr. Heidi Overton, nominee to be the next FDA Commissioner, has shared with us that she lives with type 1 diabetes.

Breaking news: for the first time in 30 years, there’s a new approved therapy for kidney disease in T1D. Today, the FDA approved finerenone (brand name Kerendia) to treat chronic kidney disease (CKD) associated with T1D. CKD is one of the most common complications of T1D—nearly one-third of people living with T1D will develop it, raising their risk of kidney failure and cardiovascular disease. Until now, their options were limited. Breakthrough T1D strategically collaborated with Bayer to support the FINE-ONE trial behind this approval. As we drive toward curing T1D, we help make everyday life better for the people who face it—starting today. Read what this approval means for the T1D community at the link below! bit.ly/4h89WUF

De la Detección Temprana a la Investigación Clínica: Avances en Diabetes Tipo 1 xitter.cf/i/broadcasts/1RKZzBnDw…

Last March, Breakthrough T1D sent a proposal to the Department of Health and Human Services (HHS) to reclassify deceased donor islets (DDIs) as organs rather than drugs. After months of engagement across HHS, the department has taken action. Today, the Food and Drug Administration (FDA) sent a request for information (RFI) to the Office of Management and Budget (OMB) for review titled “Improving Patient Access to Deceased Donor Islet Cells and Cell Products”. This is the first step in making deceased donor islets more accessible to those in the T1D community who qualify for transplants. We applaud HHS, FDA and the Health Resources and Services Administration (HRSA) for acting on this important topic. Follow Breakthrough T1D for updates on when this RFI is published so that you can make your voice heard.

Until now, clinicians have lacked concrete guidance on who, when, and how to screen for type 1 diabetes (T1D). Led by Breakthrough T1D, experts around the globe have provided practical guidance for screening. Learn more here: bit.ly/3SHCfRT

If you or a loved one lives with type 1 diabetes (T1D) and has been impacted by Hurricane Lowell, visit the link below to learn more about available resources! Stay safe! 💙 bit.ly/3BeTUaf